Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma | NEJM
Original Article from The New England Journal of Medicine — Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Related Articles
Traditional Medicare or Medicare Advantage? The Leukemia and Cancer Perspective
Today, approximately 50% of patients eligible for Medicare have opted for Medicare Advantage as their primary coverage. Whereas Medicare Advantage is a reasonable option for…
Hasbro Toys And Games, Kids Toys, Action Figures, And Board Games – Hasbro
Explore Hasbro toys and games. Shop fun toys for kids with our selection of action figures, dolls, electronic games, board games, and more on Hasbro…
The High Cost of Insulin in the United States: An Urgent Call to Action
Alec Smith was 23 when he was diagnosed with type 1 diabetes. He worked as a restaurant manager in Minnesota. At age 26, he could…
Sanofi answers the call, joining Eli Lilly, Novo Nordisk in cutting insulin prices
The world’s three premier makers of insulin are reducing prices like never before. | In a span of less than three weeks, Eli Lilly, Novo…
Drugmaker Eli Lilly caps the cost of insulin at $35 a month, bringing relief for millions
The move puts the drugmaker in line with a popular provision in the Inflation Reduction Act that capped the medication’s cost for seniors on Medicare.
How a Minnesota man who died due to insulin prices could change US healthcare forever
Alec Smith died alone in his room at age 26 because he couldn’t afford life-saving insulin. But the tragedy has sparked a movement that is…
Insulin pricing: could an e-commerce approach cut costs?
An e-commerce drug delivery approach could put a dent in upward spiraling insulin prices, but uptake challenges loom large.